FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285596384> ?p ?o ?g. }

• W4285596384 endingPage "870" @default.
• W4285596384 startingPage "870" @default.
• W4285596384 abstract "Background: The clinical impact of the functional CYP2C19 and CYP2D6 gene variants on antidepressant treatment in people with depression is not well studied. Here, we evaluate the utility of pharmacogenetic (PGx) testing in psychiatry by investigating the association between the phenotype status of the cytochrome P450 (CYP) 2C19/2D6 enzymes and the one-year risks of clinical outcomes in patients with depression with incident new-use of (es)citalopram, sertraline, or fluoxetine. Methods: This study is a population-based cohort study of 17,297 individuals who were born between 1981 and 2005 with a depression diagnosis between 1996 and 2012. Using array-based single-nucleotide-polymorphism genotype data, the individuals were categorized according to their metabolizing status of CYP2C19/CYP2D6 as normal (NM, reference group), ultra-rapid- (UM), rapid- (RM), intermediate- (IM), or poor-metabolizer (PM). The outcomes were treatment switching or discontinuation, psychiatric emergency department contacts, and suicide attempt/self-harm. By using Poisson regression analyses, we have estimated the incidence rate ratios (IRR) with 95% confidence intervals (95% CI) that were adjusted for covariates and potential confounders, by age groups (<18 (children and adolescents), 19−25 (young adults), and 26+ years (adults)), comparing the outcomes in individuals with NM status (reference) versus the mutant metabolizer status. For statistically significant outcomes, we have calculated the number needed to treat (NNT) and the number needed to genotype (NNG) in order to prevent one outcome. Results: The children and adolescents who were using (es)citalopram with CYP2C19 PM status had increased risks of switching (IRR = 1.64 [95% CI: 1.10−2.43]) and suicide attempt/self-harm (IRR = 2.67 [95% CI; 1.57−4.52]). The young adults with CYP2C19 PM status who were using sertraline had an increased risk of switching (IRR = 2.06 [95% CI; 1.03−4.11]). The young adults with CYP2D6 PM status who were using fluoxetine had an increased risk of emergency department contacts (IRR = 3.28 [95% CI; 1.11−9.63]). No significant associations were detected in the adults. The NNG for preventing one suicide attempt/suicide in the children who were using (es)citalopram was 463, and the NNT was 11. Conclusion: The CYP2C19 and CYP2D6 PM phenotype statuses were associated with outcomes in children, adolescents, and young adults with depression with incident new-use of (es)citalopram, sertraline, or fluoxetine, therefore indicating the utility of PGx testing, particularly in younger people, for PGx-guided antidepressant treatment." @default.
• W4285596384 created "2022-07-16" @default.
• W4285596384 creator A5001924044 @default.
• W4285596384 creator A5022065571 @default.
• W4285596384 creator A5051686843 @default.
• W4285596384 creator A5058495115 @default.
• W4285596384 creator A5062891274 @default.
• W4285596384 creator A5087096577 @default.
• W4285596384 creator A5090744384 @default.
• W4285596384 date "2022-07-14" @default.
• W4285596384 modified "2023-10-16" @default.
• W4285596384 title "Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study" @default.
• W4285596384 cites W2035543772 @default.
• W4285596384 cites W2054337645 @default.
• W4285596384 cites W2061591478 @default.
• W4285596384 cites W2097401631 @default.
• W4285596384 cites W2102420102 @default.
• W4285596384 cites W2102924526 @default.
• W4285596384 cites W2114185635 @default.
• W4285596384 cites W2124182596 @default.
• W4285596384 cites W2142749836 @default.
• W4285596384 cites W2147108549 @default.
• W4285596384 cites W2149492429 @default.
• W4285596384 cites W2153811106 @default.
• W4285596384 cites W2161620765 @default.
• W4285596384 cites W2301869456 @default.
• W4285596384 cites W2384461891 @default.
• W4285596384 cites W2502485509 @default.
• W4285596384 cites W2519686100 @default.
• W4285596384 cites W2528292047 @default.
• W4285596384 cites W2553123944 @default.
• W4285596384 cites W2562052809 @default.
• W4285596384 cites W2622753418 @default.
• W4285596384 cites W2747744631 @default.
• W4285596384 cites W2783960693 @default.
• W4285596384 cites W2789350728 @default.
• W4285596384 cites W2801100732 @default.
• W4285596384 cites W2889363704 @default.
• W4285596384 cites W2912304870 @default.
• W4285596384 cites W2915617238 @default.
• W4285596384 cites W2944039373 @default.
• W4285596384 cites W2964415308 @default.
• W4285596384 cites W2970080281 @default.
• W4285596384 cites W2976816195 @default.
• W4285596384 cites W3005398140 @default.
• W4285596384 cites W3025281002 @default.
• W4285596384 cites W3026116380 @default.
• W4285596384 cites W3044834917 @default.
• W4285596384 cites W3094652411 @default.
• W4285596384 cites W3107703675 @default.
• W4285596384 cites W3162308444 @default.
• W4285596384 cites W3175801695 @default.
• W4285596384 cites W3209585723 @default.
• W4285596384 cites W4200573198 @default.
• W4285596384 cites W4210495840 @default.
• W4285596384 cites W4210643740 @default.
• W4285596384 cites W4211263234 @default.
• W4285596384 cites W4245269458 @default.
• W4285596384 doi "https://doi.org/10.3390/ph15070870" @default.
• W4285596384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35890168" @default.
• W4285596384 hasPublicationYear "2022" @default.
• W4285596384 type Work @default.
• W4285596384 citedByCount "6" @default.
• W4285596384 countsByYear W42855963842022 @default.
• W4285596384 countsByYear W42855963842023 @default.
• W4285596384 crossrefType "journal-article" @default.
• W4285596384 hasAuthorship W4285596384A5001924044 @default.
• W4285596384 hasAuthorship W4285596384A5022065571 @default.
• W4285596384 hasAuthorship W4285596384A5051686843 @default.
• W4285596384 hasAuthorship W4285596384A5058495115 @default.
• W4285596384 hasAuthorship W4285596384A5062891274 @default.
• W4285596384 hasAuthorship W4285596384A5087096577 @default.
• W4285596384 hasAuthorship W4285596384A5090744384 @default.
• W4285596384 hasBestOaLocation W42855963841 @default.
• W4285596384 hasConcept C118552586 @default.
• W4285596384 hasConcept C126322002 @default.
• W4285596384 hasConcept C139719470 @default.
• W4285596384 hasConcept C140840227 @default.
• W4285596384 hasConcept C162324750 @default.
• W4285596384 hasConcept C201903717 @default.
• W4285596384 hasConcept C207103383 @default.
• W4285596384 hasConcept C2776867660 @default.
• W4285596384 hasConcept C2777490545 @default.
• W4285596384 hasConcept C2779177272 @default.
• W4285596384 hasConcept C2908647359 @default.
• W4285596384 hasConcept C33664856 @default.
• W4285596384 hasConcept C44249647 @default.
• W4285596384 hasConcept C526171541 @default.
• W4285596384 hasConcept C558461103 @default.
• W4285596384 hasConcept C62231903 @default.
• W4285596384 hasConcept C71924100 @default.
• W4285596384 hasConcept C72563966 @default.
• W4285596384 hasConcept C73269764 @default.
• W4285596384 hasConcept C77350462 @default.
• W4285596384 hasConcept C99454951 @default.
• W4285596384 hasConceptScore W4285596384C118552586 @default.
• W4285596384 hasConceptScore W4285596384C126322002 @default.
• W4285596384 hasConceptScore W4285596384C139719470 @default.

• next